Ulixertinib
MEK Mutation
BioMed Valley Discoveries, IncSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the MEK Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nst-628 Nested Therapeutics, Inc | Phase 1 | CC |
msc1936369b Day One Biopharmaceuticals, Inc. | Phase 1 | CC |
Tovorafenib Day One Biopharmaceuticals, Inc. | Phase 1 | C |
Same molecule, other indications
Ulixertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →